Salonen, Johanna
Jansa, Sanna
Vähänikkilä, Hannu
Kaarteenaho, Riitta
Funding for this research was provided by:
The Research Foundation of Pulmonary Diseases, Helsinki, Finland
The Research Foundation of North Finland
University of Oulu including Oulu University Hospital
Article History
Received: 28 April 2023
Accepted: 24 June 2023
First Online: 1 July 2023
Declarations
:
: In this retrospective study, most of the patients were deceased and no consents to participate were gathered due to the register-based nature of research in accordance with Finnish legislation and with approval of Ethical Committee of the Northern Ostrobothnia Hospital District. The study protocol was approved by the Ethical Committee of the Northern Ostrobothnia Hospital District (statement 2/2015). The study was conducted in compliance with the Declaration of Helsinki. Permission to use death certificates was given by Statistics Finland (Dnro: TK-53–515-15).
: No consents for publication were gathered since this was a retrospective study, and the majority of the patients are deceased.
: JS reports congress/travel costs from Boehringer Ingelheim, GlaxoSmithKline and Novartis Finland Oy, and lecturer’s fees from Chiesi, all outside the submitted work. SJ and HV report no conflicts of interests. RK reports consulting and lecture fees from Boehringer Ingelheim and MSD, and virtual congress costs from Roche and Novartis.